← Human Trials & Peer-Reviewed Studies
Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3
Plain-language guide to PMID 16079165 (2006): parallel-group clinical trial study of IGF-1 LR3 in 32 patients, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 16079165
- Journal
- Annals of the rheumatic diseases
- Year
- 2006
- Study type
- Clinical Trial
- Authors
- Sarzi-Puttini P et al. (5 authors)
- DOI
- 10.1136/ard.2005.040816
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3 in the context of insulin resistance, prediabetes & type 2 diabetes, published as a clinical trial.
To investigate the influence of anti-tumour necrosis factor antibody treatment (anti-TNF) with adalimumab on levels of myoglobin (degradation marker) and IGF1 in patients with rheumatoid arthritis with and without prednisolone treatment.
Why It Was Studied
Insulin-like growth factor 1 (IGF1) is an important determinant of muscle mass because it promotes growth and suppresses protein degradation.
In parallel, glucocorticoids induce IGF1 resistance and add to muscle degradation.
Who Took Part
The study group was 32 patients.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
Subcutaneous adalimumab was given to 32 patients with longstanding rheumatoid arthritis (16 with and 16 without prednisolone) in a longitudinal study.
How the Study Was Run
The design is described as parallel-group.
Groups ran in parallel: each of the patients stayed in one arm throughout.
IGF1, IGF1 binding protein 1 (IGFBP-1), IGFBP-3, and myoglobin were measured by enzyme linked immunosorbent assay.
What Was Measured
PubMed files the paper under topics including Adalimumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Rheumatoid, Drug Resistance and Glucocorticoids.
What This Means in Plain Language
The paper is a parallel-group study of IGF-1 LR3 in 32 patients in people with insulin resistance, prediabetes & type 2 diabetes.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2006 (Annals of the rheumatic diseases), a journal based in United States.
More context: the IGF-1 LR3 compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.